Supporting a Game-Changer: Proving Cost-Effectiveness of a Disruptive Technology in ADHD

[NEBA Health]

The first EEG biomarker for ADHD faces tenacious opposition from manufacturers of ADHD medications. This disruptive diagnostic has nonetheless gained interest from third party-payors. The Georgia Department of Community Health (DCH) made funding available to the client for design and implementation of a cost-effectiveness study in the Georgia Medicaid population. Despite funding availability, the client was initially unable to identify a research partner that met Georgia DCH approval. TTi drew on our extensive experience in proving cost-effectiveness of pediatric technologies to state Medicaid programs to develop a research program that met with Georgia DCH’s approval and also fit within budgetary constraints. TTi developed a four-phase program: (1) Program design / Georgia DCH approval; (2) Retrospective and prospective pilot study execution; (3) Multi-site prospective RCT; and (4) Cost-effectiveness assessment of client’s technology as an ADHD diagnostic tool. As a result of TTi’s efforts, the client will be able to fulfill their obligations to Georgia DCH and demonstrate cost-effectiveness of their technology in managing the state’s Medicaid population. The client will also be able to present a robust research program, improving physician adoption and payer coverage of their technology. Phase 3 of the four-phase effort is currently underway.